Cost-effectiveness of tenofovir in the treatment of patients with chronic hepatitis B: data from literature (original) (raw)
[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]
Giuseppe Tarantino
Clinical Management Issues, 2015
View PDFchevron_right
Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir
Rosanna Villani
Clinical Management Issues, 2015
View PDFchevron_right
Peg-interferon plus ribavirin in chronic hepatitis C: cost-efficacy and pharmacoutilization in clinical practice
angelo gatta
Farmeconomia. Health economics and therapeutic pathways, 2008
View PDFchevron_right
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study
Luisa ROMANO'
The Lancet, 2005
View PDFchevron_right
[Renal toxicity in HIV-infected patients receiving HAART including tenofovir]
Sara Melzi
Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive, 2006
View PDFchevron_right
[Effects of cascade filtration in combination with interferon and ribavirin in the treatment non responder chronic hepatitis C patients]
luigi rossi
Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
View PDFchevron_right
[Acute hepatitis C infection: epidemiological and clinical aspects, and efficacy of interferon therapy]
Sara Moneta
Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive, 2007
View PDFchevron_right
Analisi costi-efficacia di 90Y-ibritumomab tiuxetano (Zevalin®) vs. terapie attualmente disponibili nel trattamento dei pazienti affetti da Linfoma Non-Hodgkin (LNH) refrattario o recidivato
Carlo Lazzaro
Farmeconomia. Health economics and therapeutic pathways, 2005
View PDFchevron_right
Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy
Paolo Morelli
AboutOpen
View PDFchevron_right
Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy
Sergio Iannazzo
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2015
View PDFchevron_right
Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness
Andrea Marcellusi
PharmacoEconomics Italian Research Articles, 2014
View PDFchevron_right
[Computer work and De Quervain's tenosynovitis: an evidence based approach]
Piero E Cirla
Giornale italiano di medicina del lavoro ed ergonomia
View PDFchevron_right
Costs of treatment of haemophilia A in Italy: comparison of the use of plasma-derived and recombinant FVIII using a discrete event simulation (DES) model
Mario Eandi
Farmeconomia. Health economics and therapeutic pathways, 2013
View PDFchevron_right
Costo-efficacia di rituximab nella terapia di mantenimento in soggetti affetti da linfoma non-Hodgkin follicolare refrattario o recidivante
Stefania Lopatriello
PharmacoEconomics Italian Research Articles, 2007
View PDFchevron_right
Фармакокинетика инновационного липосомального препарата для лечения гепатита C
Валерий Валерьевич Смирнов
Экспериментальная и клиническая фармакология, 2019
View PDFchevron_right
Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteratura
G. Rivolta
PharmacoEconomics Italian Research Articles, 2006
View PDFchevron_right
Management of hepatocellular carcinoma: international guidelines
Maurizio Grosso
Italian Journal of Medicine, 2013
View PDFchevron_right
Analisi di costo efficacia nella terapia della BPCO
Sergio Iannazzo
Farmeconomia. Health economics and therapeutic pathways, 2005
View PDFchevron_right
Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare
Giovanni Pellicanò
JHA - Journal of HIV and Ageing
View PDFchevron_right
HBV-DNA as marker of hepatitis B virus infection in autochthonous and foreign population of the Molecular Biology Laboratory of the Immuno-Haematology and Blood Transfusion Unit, AO “S. Maria”, Terni
Valentina Grespi
Microbiologia Medica, 2014
View PDFchevron_right
Tiotropium bromide in the routine care of GOLD stage II COPD patients: a pharmaeconomic evaluation
Sergio Iannazzo
Farmeconomia. Health economics and therapeutic pathways, 2011
View PDFchevron_right
Effetti dell'introduzione del prezzo di riferimento per gli inibitori di pompa protonica sul comportamento diagnostico-terapeutico in Medicina Generale
Enzo Ubaldi
Rivista della Società …, 2008
View PDFchevron_right